Kalydeco and Orkambi are very good examples of a new era of highly specialised medicines effective for some people with cystic fibrosis.
These new and innovative medicines are extremely expensive. PHARMAC has a limited budget, so CFNZ reluctantly accept that they must consider cost-effectiveness when prioritising funding.
If PHARMAC fund expensive medicines, there is less money available for treating other New Zealanders – including those with cystic fibrosis.
The only way to make these new and expensive treatments available to people with cystic fibrosis is to change the way PHARMAC considers and funds them.
CFNZ will be gathering information from patients and health professionals to prioritise and coordinate our battles for increased access to treatment, equipment and medications for the whole cystic fibrosis community. That is why CFNZ is not, at this point in time, undertaking a campaign for specific high-cost medicines.
To deal with the challenge of high cost innovative medicines we have decided to work with the rare disorders community to collectively campaign for increased funding of PHARMAC.